Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Loxoprofen. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 17/20 | 1.00 |
| ▸ | PTGS2 known ✓ | P35354 | 17/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | MT-CO1 | P00395 | 1/20 | 0.59 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Loxoprofen SCHEMBL8754892 | 1.00 | PTGS1 (1.00) | PTGS1PTGS2OPRK1HTTKMT2A | |
| Loxoprofen SCHEMBL28562193 | 1.00 | PTGS1 (1.00) | PTGS1PTGS2OPRK1HTTKMT2A | |
| Loxoprofen SCHEMBL28914090 | 1.00 | PTGS1 (1.00) | PTGS1PTGS2OPRK1HTTKMT2A | |
| Loxoprofen SCHEMBL28562194 | 1.00 | PTGS1 (1.00) | PTGS1PTGS2OPRK1HTTKMT2A | |
| Loxoprofen SCHEMBL28914092 | 1.00 | PTGS1 (1.00) | PTGS1PTGS2OPRK1HTTKMT2A | |
| Loxoprofen SCHEMBL11133884 | 1.00 | PTGS1 (1.00) | PTGS1PTGS2OPRK1HTTKMT2A | |
| Loxoprofen SCHEMBL14312087 | 1.00 | PTGS1 (1.00) | PTGS1PTGS2OPRK1HTTKMT2A | |
| Loxoprofen SCHEMBL33007 | 0.99 | PTGS1 (0.97) | PTGS1PTGS2OPRK1HTTKMT2A | |
| Loxoprofen SCHEMBL28213966 | 0.99 | PTGS1 (0.97) | PTGS1PTGS2OPRK1HTTKMT2A | |
| Loxoprofen SCHEMBL190158 | 0.97 | PTGS1 (0.95) | PTGS1PTGS2OPRK1HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 15222 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3841097-B1 | 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER | BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS BRFAA (GR) | 2026-05-20 | — | — | EP | claimed |
| CN-122031445-A | External pharmaceutical composition containing loxoprofen | 第一三共健康事业株式会社 | 2026-05-15 | — | — | CN | claimed |
| CN-122031446-A | External pharmaceutical composition containing loxoprofen and felbinac | 第一三共健康事业株式会社 | 2026-05-15 | — | — | CN | claimed |
| CN-122031449-A | External pharmaceutical composition containing loxoprofen and diclofenac | 第一三共健康事业株式会社 | 2026-05-15 | — | — | CN | claimed |
| US-20260130854-A1 | PREPARATION OF NANO LINIMENT FOR EXTERNAL TREATMENT OF GOUT | Zhang, Boke (US) | 2026-05-14 | — | — | US | claimed |
| US-20260130853-A1 | METHOD OF TREATING GOUT BY TOPICAL APPLICATION OF NANO LINIMENT | Zhang, Boke (US) | 2026-05-14 | — | — | US | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| US-12605432-B2 | Combinations for antigen based therapy | DIAMYD MEDICAL AB (SE) | 2026-04-21 | — | — | US | claimed |
| US-12600696-B2 | Aromatic compounds | Xeniopro GmbH (DE) | 2026-04-14 | — | — | US | claimed |
| US-12590075-B2 | Refining method | NGK INSULATORS, LTD. (JP) | 2026-03-31 | — | — | US | claimed |
| US-5330981-A | Antiinflammatory agents | ISTITUTO GENTILI S.P.A. (IT) | 1994-07-19 | — | — | US | claimed |
| EP-0484529-B1 | SKIN CREAM PREPARATION FOR EXTERNAL USE | HISAMITSU PHARMACEUTICAL CO (JP) | 1994-04-27 | — | — | EP | claimed |
| US-5271939-A | Pharmaceutical compositions and methods of treatment to prevent and treat corneal scar formation produced by laser irradiation | ALCON LABORATORIES, INC. (US) | 1993-12-21 | — | — | US | claimed |
| EP-0569411-A1 | ACYLAMINO-ALKYLIDEN-HYDROXY-BISPHOSPHONIC ACIDS USEFUL IN THE THERAPY OF OSTEOARTICULAR DISEASES. | GENTILI IST SPA (IT) | 1993-11-18 | — | — | EP | claimed |
| EP-0537313-A1 | ARYLALKYL ESTERS OF 4,5-DIHYDROXY-9,10-DIHYDRO-9,10-DIOXO-2-ANTHRACENECARBOXYLIC ACID HAVING THERAPEUTICAL ACTIVITY. | GENTILI IST SPA (IT) | 1993-04-21 | — | — | EP | claimed |
| EP-0331471-B1 | HIGH MOLECULAR WEIGHT PRODRUG DERIVATIVES OF ANTIINFLAMMATORY DRUGS | Larsen, Claus Selch (DK) | 1992-12-16 | — | — | EP | claimed |
| WO-1992019584-A1 | ARYLALKYL ESTERS OF 4,5-DIHYDROXY-9,10-DIHYDRO-9,10-DIOXO-2-ANTHRACENECARBOXYLIC ACID HAVING THERAPEUTICAL ACTIVITY | ISTITUTO GENTILI S.P.A. (IT) | 1992-11-12 | — | — | WO | claimed |
| WO-1992013864-A1 | ACYLAMINO-ALKYLIDEN-HYDROXY-BISPHOSPHONIC ACIDS USEFUL IN THE THERAPY OF OSTEOARTICULAR DISEASES | ISTITUTO GENTILI S.P.A. (IT) | 1992-08-20 | — | — | WO | claimed |
| EP-0331471-A1 | High molecular weight prodrug derivatives of antiinflammatory drugs | Larsen, Claus Selch (DK) | 1989-09-06 | — | — | EP | claimed |
| US-4161538-A | 4-(2-OXO- OR HYDROXIMINO-CYCLOALKAN-1-YLMETHYL)-PHENYLACETIC ACID, ANTIINFLAMMATORY AGENTS | SANKYO COMPANY LIMITED (JP) | 1979-07-17 | — | — | US | claimed |